clinical trial · NCT07211958
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Acute Myeloid LeukemiasRevumenibPlaceboIntensive Chemotherapy Regimen
brief summary
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
started
Nov 25, 2025
primary completion
Jun 1, 2029
completion
Jan 1, 2031
last updated
May 4, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol